Literature DB >> 26766888

Alirocumab (Praluent): First in the New Class of PCSK9 Inhibitors.

Marina Manniello, Michele Pisano.   

Abstract

Alirocumab (Praluent): first in the new class of PCSK9 inhibitors.

Entities:  

Year:  2016        PMID： 26766888      PMCID： PMC4699483     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


  8 in total

1.  2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.

Authors:  Neil J Stone; Jennifer G Robinson; Alice H Lichtenstein; C Noel Bairey Merz; Conrad B Blum; Robert H Eckel; Anne C Goldberg; David Gordon; Daniel Levy; Donald M Lloyd-Jones; Patrick McBride; J Sanford Schwartz; Susan T Shero; Sidney C Smith; Karol Watson; Peter W F Wilson
Journal:  J Am Coll Cardiol       Date:  2013-11-12       Impact factor: 24.094

2.  Cardiology patient page. Statin intolerance.

Authors:  David H Fitchett; Robert A Hegele; Subodh Verma
Journal:  Circulation       Date:  2015-03-31       Impact factor: 29.690

3.  Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial.

Authors:  Gregory G Schwartz; Laurence Bessac; Lisa G Berdan; Deepak L Bhatt; Vera Bittner; Rafael Diaz; Shaun G Goodman; Corinne Hanotin; Robert A Harrington; J Wouter Jukema; Kenneth W Mahaffey; Angèle Moryusef; Robert Pordy; Matthew T Roe; Tyrus Rorick; William J Sasiela; Cheerag Shirodaria; Michael Szarek; Jean-François Tamby; Pierluigi Tricoci; Harvey White; Andreas Zeiher; Philippe Gabriel Steg
Journal:  Am Heart J       Date:  2014-08-07       Impact factor: 4.749

4.  Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I study.

Authors:  Dean J Kereiakes; Jennifer G Robinson; Christopher P Cannon; Christelle Lorenzato; Robert Pordy; Umesh Chaudhari; Helen M Colhoun
Journal:  Am Heart J       Date:  2015-03-13       Impact factor: 4.749

5.  Efficacy and safety of alirocumab in reducing lipids and cardiovascular events.

Authors:  Jennifer G Robinson; Michel Farnier; Michel Krempf; Jean Bergeron; Gérald Luc; Maurizio Averna; Erik S Stroes; Gisle Langslet; Frederick J Raal; Mahfouz El Shahawy; Michael J Koren; Norman E Lepor; Christelle Lorenzato; Robert Pordy; Umesh Chaudhari; John J P Kastelein
Journal:  N Engl J Med       Date:  2015-03-15       Impact factor: 91.245

Review 6.  Statins for the primary prevention of cardiovascular disease.

Authors:  Fiona Taylor; Mark D Huffman; Ana Filipa Macedo; Theresa H M Moore; Margaret Burke; George Davey Smith; Kirsten Ward; Shah Ebrahim
Journal:  Cochrane Database Syst Rev       Date:  2013-01-31

7.  Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia not adequately controlled with current lipid-lowering therapy: design and rationale of the ODYSSEY FH studies.

Authors:  John J P Kastelein; Jennifer G Robinson; Michel Farnier; Michel Krempf; Gisle Langslet; Christelle Lorenzato; Daniel A Gipe; Marie T Baccara-Dinet
Journal:  Cardiovasc Drugs Ther       Date:  2014-06       Impact factor: 3.727

8.  ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia.

Authors:  John J P Kastelein; Henry N Ginsberg; Gisle Langslet; G Kees Hovingh; Richard Ceska; Robert Dufour; Dirk Blom; Fernando Civeira; Michel Krempf; Christelle Lorenzato; Jian Zhao; Robert Pordy; Marie T Baccara-Dinet; Daniel A Gipe; Mary Jane Geiger; Michel Farnier
Journal:  Eur Heart J       Date:  2015-09-01       Impact factor: 29.983
  8 in total
  3 in total

Review 1.  Vaccines Targeting PCSK9: A Promising Alternative to Passive Immunization with Monoclonal Antibodies in the Management of Hyperlipidaemia?

Authors:  Stefan Weisshaar; Markus Zeitlinger
Journal:  Drugs       Date:  2018-06       Impact factor: 9.546

2.  The annual rate of coronary artery calcification with combination therapy with a PCSK9 inhibitor and a statin is lower than that with statin monotherapy.

Authors:  Yuichi Ikegami; Ikuo Inoue; Kaiji Inoue; Yuichi Shinoda; Shinichiro Iida; Seiichi Goto; Takanari Nakano; Akira Shimada; Mistuhiko Noda
Journal:  NPJ Aging Mech Dis       Date:  2018-06-22

3.  Hepatic Sensing Loop Regulates PCSK9 Secretion in Response to Inhibitory Antibodies.

Authors:  Carlota Oleaga; Michael D Shapiro; Joshua Hay; Paul A Mueller; Joshua Miles; Cecilia Huang; Emily Friz; Hagai Tavori; Peter P Toth; Cezary Wójcik; Bruce A Warden; Jonathan Q Purnell; P Barton Duell; Nathalie Pamir; Sergio Fazio
Journal:  J Am Coll Cardiol       Date:  2021-10-05       Impact factor: 24.094
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.